Previous Close | 4.2000 |
Open | 4.4000 |
Bid | 1.7000 |
Ask | 4.2000 |
Strike | 7.50 |
Expire Date | 2024-07-19 |
Day's Range | 4.2000 - 4.4000 |
Contract Range | N/A |
Volume | |
Open Interest | 1.79k |
Annexon (ANNX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
BRISBANE, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on May 11, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4). In the aggreg
Just because a business does not make any money, does not mean that the stock will go down. For example, although...